RxDoctor Payments Data

Amir Ali, MD

Internal Medicine · Houston, TXNPI 1750482691

Payments from drug & device makers

$1,035in general payments, 2019–2025

Across 33 payments — averaging $31.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$391
  • Covidien LP$156
  • GSK$115
  • GE HealthCare$69
  • Abbott$64
  • Smith+Nephew$51
  • plus $189 from 6 others

What the payments were for

  • Food & beverage$1,035100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,035 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$45,018
Medicare patients
78
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$140,380
FarxigaDapagliflozin Propanediol74$97,719
TrulicityDulaglutide42$79,333
JanuviaSitagliptin Phosphate40$58,271
JardianceEmpagliflozin36$55,572
EliquisApixaban24$40,145
MounjaroTirzepatide20$30,727
TradjentaLinagliptin19$28,323
XareltoRivaroxaban19$20,304
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$19,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$14,538
BrilintaTicagrelor11$13,406
Tresiba Flextouch U-200Insulin Degludec11$10,378
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$4,938
Atorvastatin Calcium618$4,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$33$140,38073 claims
AstraZenecaFarxiga, Brilinta$391$111,12585 claims
Boehringer IngelheimJardiance, Tradjenta$37$83,89555 claims
GSKTrelegy Ellipta$115$14,53811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →